Evaluation and Management of Low DHEAS in Middle‑Aged Women
Clinical Significance
- A DHEAS concentration of 14 µg/dL in a healthy 47‑year‑old woman is markedly below the expected range and should prompt investigation for primary adrenal insufficiency (PAI). 1
- Low DHEAS is a sensitive early marker of adrenal dysfunction and should not be dismissed as a normal consequence of aging. 1
- In a 47‑year‑old woman, age‑appropriate reference values are typically > 30–40 µg/dL; values far below this range raise concern for pathology. 2
Initial Diagnostic Work‑up
- Obtain an 8 AM fasting serum cortisol and a simultaneous plasma ACTH measurement on the same blood draw. 1
- Screening thresholds for PAI: DHEAS markedly low together with a morning cortisol < 5 µg/dL and an ACTH level > 2 × the upper limit of normal strongly suggest primary adrenal insufficiency. 1
- If the 8 AM cortisol is < 10 µg/dL, proceed to a high‑dose (250 µg) ACTH (cosyntropin) stimulation test to confirm or exclude adrenal insufficiency. 1
- ACTH stimulation interpretation: After a 250 µg ACTH dose, a peak cortisol < 18–20 µg/dL (500–550 nmol/L) at 30 or 60 minutes confirms adrenal insufficiency. 1
- When cortisol is < 5 µg/dL with ACTH > 66 pmol/L, PAI is highly likely; initiate glucocorticoid replacement and evaluate etiology (autoimmune antibodies, imaging). 1
- If cortisol is 5–10 µg/dL, the ACTH stimulation test is required; if cortisol > 10 µg/dL with a normal ACTH, PAI is unlikely and other causes of isolated low DHEAS should be explored. 1
Excluding Exogenous Glucocorticoid Suppression
- Review medication history for any glucocorticoid exposure, including inhaled steroids used > 1 year, high‑dose topical preparations, intra‑articular injections within the past 2 months, and concomitant CYP3A4 inhibitors, as these can suppress the hypothalamic‑pituitary‑adrenal axis and lower DHEAS. 3
Differential Diagnosis
| Condition | Key Laboratory/Imaging Features | Guideline Reference |
|---|---|---|
| Functional hypothalamic amenorrhea (FHA) | Low DHEAS with low gonadotropins (LH/FSH < 10 IU/L) and low estradiol (< 50 pg/mL). | 4 |
| Hypopituitarism (central adrenal insufficiency) | Low DHEAS, low cortisol, inappropriately normal or low ACTH; brain MRI of the pituitary indicated. | 4 |
| Subclinical hypercortisolism (autonomous cortisol secretion) | Low DHEAS with normal or elevated cortisol; consider adrenal imaging and overnight dexamethasone suppression if an adrenal mass is present. (Not cited – excluded per instruction) | — |
Therapeutic Recommendations
- Routine DHEA supplementation is not advised in women without confirmed adrenal insufficiency, as the Endocrine Society finds insufficient efficacy and safety data. 5
- DHEA therapy may be considered only in patients with confirmed primary adrenal insufficiency who have persistent symptoms despite optimized glucocorticoid replacement, after a documented 6‑month trial demonstrating benefit. The typical dose is 25–50 mg orally daily, with DHEAS re‑measurement after 6 months aiming for the mid‑normal premenopausal range; discontinue if no sustained clinical improvement. 7
Management of Confirmed Primary Adrenal Insufficiency
- Initiate hydrocortisone replacement (15–25 mg per day divided into two or three doses) and add fludrocortisone when primary adrenal failure is confirmed. Provide patient education on stress‑dosing and supply an emergency injectable hydrocortisone kit. 1
Follow‑up and Monitoring
- If adrenal insufficiency is excluded, repeat the DHEAS measurement in 6–12 months to verify stability; concurrently evaluate for other potential contributors such as thyroid disease, anemia, or sleep disorders. 3
- When DHEA supplementation is undertaken (per the criteria above), monitor morning DHEAS after 6 months and assess clinical response; discontinue therapy if benefit is not evident. 7